ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Deep immunoglobulin repertoire sequencing depicts a comprehensive atlas of spike-specific antibody lineages shared among COVID-19 convalescents

Yan, Qihong; Zhang, Yudi; Hou, Ruitian; Pan, Wenjing; Liang, Huan; Gao, Xijie; Deng, Weiqi; Huang, Xiaohan; Qu, Linbing; Tang, Congli; He, Ping; Liu, Banghui; Wang, Qian; Zhao, Xinwei; Lin, Zihan; Chen, Zhaoming; Li, Pingchao; Han, Jian; Xiong, Xiaoli*; Zhao, Jincun; Li, Song; Niu, Xuefeng; Chen, Ling*广州医学院; 中国科学院研究生院; 中国科学院; 1; 5
Emerging Microbes & Infections2024-12-31DOI: 10.1080/22221751.2023.2290841
6阅读
引用收藏
分享

摘要

Neutralizing antibodies are a key component in protective humoral immunity against SARS-CoV-2. Currently, available technologies cannot track epitope-specific antibodies in global antibody repertoires. Thus, the comprehensive repertoire of spike-specific neutralizing antibodies elicited by SARS-CoV-2 infection is not fully understood. We therefore combined high-throughput immunoglobulin heavy chain (IgH) repertoire sequencing, and structural and bioinformatics analysis to establish an antibodyomics pipeline, which enables tracking spike-specific antibody lineages that target certain neutralizing epitopes. We mapped the neutralizing epitopes on the spike and determined the epitope-preferential antibody lineages. This analysis also revealed numerous overlaps between immunodominant neutralizing antibody-binding sites and mutation hotspots on spikes as observed so far in SARS-CoV-2 variants. By clustering 2677 spike-specific antibodies with 360 million IgH sequences that we sequenced, a total of 329 shared spike-specific antibody clonotypes were identified from 33 COVID-19 convalescents and 24 SARS-CoV-2-naive individuals. Epitope mapping showed that the shared antibody responses target not only neutralizing epitopes on RBD and NTD but also non-neutralizing epitopes on S2. The immunodominance of neutralizing antibody response is determined by the occurrence of specific precursors in human naive B-cell repertoires. We identified that only 28 out of the 329 shared spike-specific antibody clonotypes persisted for at least 12 months. Among them, long-lived IGHV3-53 antibodies are likely to evolve cross-reactivity to Omicron variants through accumulating somatic hypermutations. Altogether, we created a comprehensive atlas of spike-targeting antibody lineages in COVID-19 convalescents and antibody precursors in human naive B cell repertoires, providing a valuable reference for future vaccine design and evaluation.

学科与关键词

关键词
SARS-CoV-2spikeantibodyomicsantibody repertoireepitope mappinglineage tracking
相关
加载中…
  • Germline IGHV3-53-encoded RBD-targeting neutralizing antibodies are commonly present in the antibody repertoires of COVID-19 patients
    Yan, Qihong; He, Ping; Huang, Xiaohan; Luo, Kun; Zhang, Yudi; Yi, Haisu; Wang, Qian; Li, Feng; Hou, Ruitian; Fan, Xiaodi; Li, Pingchao; Liu, Xinglong; Liang, Huan; Deng, Yijun; Chen, Zhaoming; Chen, Yunfei; Mo, Xiaoneng; Feng, Liqiang; Xiong, Xiaoli; Li, Song; Han, Jian; Qu, Linbing*; Niu, Xuefeng*; Chen, Ling*Emerging Microbes & Infections, 2021, 10(1): 1097-1111.被引 17
  • Shared IGHV1-69-encoded neutralizing antibodies contribute to the emergence of L452R substitution in SARS-CoV-2 variants
    Yan, Qihong; Hou, Ruitian; Huang, Xiaohan; Zhang, Yanjun; He, Ping; Zhang, Yudi; Liu, Banghui; Wang, Qian; Rao, Haiyue; Chen, Xianying; Zhao, Xinwei; Niu, Xuefeng; Zhao, Jincun*; Xiong, Xiaoli*; Chen, Ling*Emerging Microbes & Infections, 2022, 11(1): 2749-2761.被引 5
  • Immunodominant antibody germlines in COVID-19
    Andreano Emanuele; Rappuoli RinoJournal of Experimental Medicine, 2021, 218(5).被引 22
查看全部 →

发表信息

论文状态
公开发表
期刊
Emerging Microbes & Infections
发表日期
2024-12-31
卷期
第 13 卷, 第 1 期
页码
2290841
DOI
10.1080/22221751.2023.2290841
语言
ENGLISH
成果收录
SCIE
资助标注
National Natural Science Foundation of China [82201932, 92269201, 61971187, 32170941]; National Natural Science Foundation of China [2022M710891]; China Postdoctoral Science Foundation [SKLRD-Z-202324]; State Key Laboratory of Respiratory Disease [2060206-202201020428]; Guangzhou Science and Technology Bureau - Municipal Schools and Colleges

作者

  • Y

    Yan, Qihong (第一作者)

    chinese acad sci · 1 · guangzhou med univ

  • Z

    Zhang, Yudi

    chinese acad sci · univ chinese acad sci

查看全部 23 位作者收起作者
  • H

    Hou, Ruitian

    guangzhou med univ

  • P

    Pan, Wenjing

    univ south china

  • L

    Liang, Huan

    1 · guangzhou med univ

  • G

    Gao, Xijie

    5 · guangzhou med univ

  • D

    Deng, Weiqi

    chinese acad sci · univ chinese acad sci

  • H

    Huang, Xiaohan

    1 · guangzhou med univ · chinese acad sci

  • Q

    Qu, Linbing

    chinese acad sci

  • T

    Tang, Congli

  • H

    He, Ping

    chinese acad sci

  • L

    Liu, Banghui

    chinese acad sci

  • W

    Wang, Qian

  • Z

    Zhao, Xinwei

    chinese acad sci

  • L

    Lin, Zihan

    chinese acad sci · univ chinese acad sci

  • C

    Chen, Zhaoming

    chinese acad sci

  • L

    Li, Pingchao

    chinese acad sci

  • H

    Han, Jian

  • X

    Xiong, Xiaoli (通讯)

    chinese acad sci

  • Z

    Zhao, Jincun

    1 · guangzhou med univ

  • L

    Li, Song

    univ south china

  • N

    Niu, Xuefeng

    1 · guangzhou med univ

  • C

    Chen, Ling (通讯)

    chinese acad sci · guangzhou med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417